中国医院用药评价与分析2025，Vol.25Issue(3)：352-357,6.DOI:10.14009/j.issn.1672-2124.2025.03.021
安徽省某三级综合医院恶性肿瘤患者的分布及抗肿瘤药物的使用情况分析
Distribution of Malignant Tumor Patients and Application of Anti-Tumor Drugs in a Grade Ⅲ General Hospital in Anhui
摘要
Abstract
OBJECTIVE:To investigate the age and gender distribution of malignant tumor inpatients and application of anti-tumor drugs in outpatient pharmacy in a grade Ⅲ general hospital(hereinafter referred to as"the hospital")in Anhui in 2023,so as to provide references for promoting the prevention and treatment of tumor diseases in county-level hospitals and the rational application of anti-tumor drugs.METHODS:Information of malignant tumor patients in the hospital in 2023 was retrieved to analyze the age and gender distribution,application of anti-tumor drugs in the outpatient pharmacy of the hospital in 2023 was retrieved to analyze the parameters such as the consumption amount,consumption sum,defined daily dose(DDD),defined daily dose system(DDDs),defined daily cost(DDC)and sequence of drug consumption sum(B)/sequence of DDDs(A).RESULTS:In 2023,the top 3 malignant tumors ranked by the number of patients in the hospital were respectively lung cancer,liver cancer and intestinal cancer,the number of male patients was higher than that of female patients for all 3 malignant tumors mentioned above,the number of patients was positively correlated with age,and the number of patients increased rapidly after the age of 40 years,patients with lung cancer and intestinal cancer were mostly aged>70 to 80 years,while patients with liver cancer were relatively young,being in the range of>50 to 60 years.The anti-tumor drugs in outpatient pharmacy were mainly small-molecule targeted drugs,including 27 tyrosine kinase inhibitors(TKI).In 2023,the TKI with the largest consumption amount in the outpatient pharmacy was icotinib;the top 1 TKI ranked by consumption sum was osimertinib;the top 3 TKI ranked by DDDs were respectively icotinib,anlotinib and osimertinib,with icotinib having the DDC of 5.17 RMB and B/A of 3.00,which showed a good synchronization.Osimertinib and flumatinib had the lowest B/A of 0.33,with the worst synchronization among the 27 TKI.CONCLUSIONS:The application of anti-tumor drugs in outpatient pharmacy of the hospital in 2023 is reasonable in general,but it is still necessary to further strengthen the supervision to reduce the burden on patients and ensure more economical efficiency and safety of medication.关键词
恶性肿瘤/年龄分布/抗肿瘤药物/销售金额/用药频度/限定日费用/排序比Key words
Malignant tumor/Age distribution/Anti-tumor drugs/Consumption sum/Defined daily dose system/Defined daily cost/Ranking ratio分类
医药卫生引用本文复制引用
李晓琦,庞一迪,庞晓青..安徽省某三级综合医院恶性肿瘤患者的分布及抗肿瘤药物的使用情况分析[J].中国医院用药评价与分析,2025,25(3):352-357,6.基金项目
国家自然科学基金资助项目(No.82204930) （No.82204930）
江苏省中医药科技发展计划青年人才项目(No.QN202110) （No.QN202110）
